Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia

“…Finally, the ORR of MDS-EB-1 in this paper was 75.0%, with a median survival time of 11.5 months and ORR of MDS-EB-2. It was 62.5% with a median survival time of 6.5 (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19) months, suggesting that azacytidine and B-cell lymphoma/leukemia-2 inhibitors may be more effective than MDS-EB-2 in the treatment of MDS-EB-2. This seems to be consistent with the [20].…”

“…Adopted in fiscal 2006 MDS International Clinical Working Group (IWG 2006), efficacy evaluation criteria are judged, which mainly include complete remission (complete remission, CR), partial mitigation (partial remission, PR), bone marrow remission (marrow CR, mCR), hematology improved (hematological improve, HI) disease stabilization, and treatment failure: (1) CR: blast cells in the bone marrow < 5.0% simultaneously satisfy all cell lines with normal, peripheral blood neutrophil counts 21.0 ∗ 10 9 /L, hemoglobin 2110 g/L, platelet count 2100 ∗ 10 9 /L, and blast cells 0%; (2) mCR: the content of blast cells in the bone marrow < 5.0% decreases by 50.0% compared to before treatment, but if the peripheral blood reaches HIS, it could also be indicated; (3) PR: absolute peripheral blood values should be maintained for at least 2 months, with other requirements meeting the criteria for complete remission (in patients who are abnormal before treatment), but the total number of blast cells in the bone marrow is only 50.0% less than the overall number before treatment and still exceeds 5.0% regardless of the degree and morphology of cell proliferation; and (4) CR or PR recurrence after recurrence: at least one of the following should be included: (1) the proportion of bone marrow blast cells has returned to the proportion before chemotherapy; (2) the decrease in hemoglobin exceeds 15 g/L or rely entirely on blood transfusions; (3) 250.0% reduction in platelet or granulocyte count compared to optimal efficacy; (5) disease stability does not meet the minimum criteria for partial remission, but there is no evidence of progression of the disease for at least 8 weeks; (6) treatment failure: the patient dies or progresses with disease while receiving treatment development includes exacerbation of decreased blood cells, an increase in the proportion of blast cells in the bone marrow or the development of more severe than before treatment FAB subtypes; (7) HI: patients are assessed for hematological improvement based on the results of blood cell analysis and a decrease in red blood cell transfusion; and (8) total remission rate (overall response rate, ORR) = (CR + PR + mCR)/total number of patients ∗ 100%. Adverse reactions occur during chemotherapy, see WHO evaluation criteria for indexes for the evaluation of adverse drug reactions during acute and subacute chemotherapy [ 13 ], which mainly include hematological toxicity and nonhematogenous, blood toxicity mainly such as decreased white blood cells, platelets, granulocytes, and decreased hemoglobin; nonhematogenous has gastrointestinal tract, liver function damage, kidneys, bladder, heart and nervous system abnormal symptoms, and positive signs, for the results of genetic mutations, the basis IWG 2006 efficacy evaluation criteria, and comprehensive analysis of gene polymorphisms for azacytidine treatment AML/MDS effects of efficacy and prognosis.…”

“…Based on disease typing analysis, MDS-EB-1 was 4 cases, ORR was 75.0% (3/4), CR was 1 case, mCR was 2 cases, and accompaniment was HI1. In one case, the median survival time was 11.5 (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22) months for 1 case with disease stabilization, the MDS-EB-2 was 8 cases, the ORR was 62.5% (5/8), and the mCR was 5. In 3 cases, the disease was stable, and the median survival time was 6.5 (3 to 19) months.…”

“…1 case of CR, 3 cases of mCR, 1 case with HI, and 1 case of stable disease were as follows. As of February 1, 2021, the above median survival times were 13 (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22), 11 (8.5-22), and 13 (8.5-22) months, respectively. There were 9 cases of MDS comutation, ORR was 55.5% (5/ 9), CR was 1 case, mCR was 4 cases, with HI 1 patient, disease stable 4 patients, median survival time > AML comorbid mutation 5 patients, ORR of 60.0% (3/5), mCR 3 patients with 1 case of HI, and 2 cases of treatment failure, and the median survival time was 13 (3-14) months, see Table 3.…”

“…) disease stability does not meet the minimum criteria for partial remission, but there is no evidence of progression of the disease for at least 8 weeks; (6) treatment failure: the patient dies or progresses with disease while receiving treatment development includes exacerbation of decreased blood cells, an increase in the proportion of blast cells in the bone marrow or the development of more severe than before treatment FAB subtypes; (7) HI: patients are assessed for hematological improvement based on the results of blood cell analysis and a decrease in red blood cell transfusion; and (8) total remission rate ðoverall response rate, ORRÞ = ðCR + PR + mCRÞ/total number of patients * 100%. Adverse reactions occur during chemotherapy, see WHO evaluation criteria for indexes for the evaluation of adverse drug reactions during acute and subacute chemotherapy[13], which mainly include hematological toxicity and nonhema-…”